Liprin-α4 as a new therapeutic target for SCLC as an upstream mediator of HIF1α

Hideya Onishi, Akio Yamasaki, Katsuya Nakamura, Shu Ichimiya, Kosuke Yanai, Masayo Umebayashi, Shuntaro Nagai, Takashi Morisaki

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Background/Aim: Small-cell lung cancer (SCLC) remains one of deadliest types of cancers. Cis-diamminedichloroplatinum (CDDP) is a key chemotherapeutic agent for SCLC, however, its therapeutic effect is limited. Recently, hypoxia in the cancer microenvironment has been suggested to influence the effect of cancer therapy. Materials and Methods: Using small interfering RNA inhibition of leukocyte common antigen-related interacting protein alpha 4 (liprin-α4), and of hypoxia-inducible factor (HIF)-1α, proliferation, invasion, migration and chemosensitivity were investigated in SBC-5 SCLC cells, under normoxia and hypoxia. Results: Liprin-α4 was found to contribute to proliferation, but not migration and invasion of SBC-5 cells both under normoxia and hypoxia. Inhibition of liprin-α4 increased chemosensitivity of SBC-5 cells under hypoxia. Liprin-α4 signaling occurs through mitogen-activated protein kinase pathways via activation of HIF1α expression. Inhibition of HIF1α reduced proliferation and increased chemosensitivity of SBC-5 cells under hypoxia. Conclusion: Liprin-α4 inhibition may enhance the effect of CDDP and liprin-α4 might be a novel therapeutic target in SCLC.

Original languageEnglish
Pages (from-to)1179-1184
Number of pages6
JournalAnticancer research
Issue number3
Publication statusPublished - Mar 1 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Liprin-α4 as a new therapeutic target for SCLC as an upstream mediator of HIF1α'. Together they form a unique fingerprint.

Cite this